Nematode Infections: Clinical Trials

31 trials for Nematode Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 4 not yet recruiting, 3 unknown, 2 recruiting. 31 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 331Completed 20, Not yet recruiting 4, Unknown 3, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 24Completed 3, Unknown 1

Follow Nematode Infections: new trials by email Literature Review of Nematode Infections trials Research Report on Nematode Infections

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
emodepside (BAY 44-4400), Mebendazole 100 MG, similar placebo to mebendazole - Trichuris Trichiura; Infection, Hookworm Infection
Phase 3Not yet recruitingSwiss Tropical & Public Health Institute3152026-11-062026-08-14
Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras
Placebo, Albendazole 400 mg, Albendazole Plus Ivermectin - Trichuriasis, Strongyloidiasis
Phase 3Not yet recruitingMundo Sano Foundation3682026-11-012026-06-23
Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda
Albendazole 400mg, Ivermectin 3 mg - Ascariasis
Phase 3Not yet recruitingJennifer Keiser4502026-10-012026-10-14
Better Options for Lymphatic Filariasis Treatment
MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies
Phase 3RecruitingMedicines Development for Global Health51002026-09-282026-10-07
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection
Phase 3CompletedSwiss Tropical & Public Health Institute3152025-11-252026-10-08
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths
Phase 3RecruitingInsud Pharma200002025-09-012025-09-15
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Albendazole 400mg, Placebo - Loiasis With Positive Blood Microfilaremia, Loiasis
Phase 3Not yet recruitingProgramme National de Lutte contre l'Onchocercose, Republic of the Congo1002025-01-152024-09-26
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
Levamisole 3 days, Levamisole 5 days, Placebo - Loiasis
Phase 2 / Phase 3UnknownProgramme National de Lutte contre l'Onchocercose, Republic of the Congo992024-06-212024-09-20
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Placebo Moxidectin - Trichuriasis, Ascariasis
Phase 3CompletedJennifer Keiser2242024-05-142025-09-19
Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura
IVM (200 µg/kg) + ALB (400 mg), ALB (400mg) - Trichuriasis
Phase 3CompletedJennifer Keiser1612023-10-092024-04-10
Efficacy and Safety of MOX/ALB Co-administration
Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Ivermectin 3 mg Oral Tablet - Trichuriasis, Ascariasis
Phase 3CompletedJennifer Keiser2552021-06-152024-01-24
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Moxidectin, Ivermectin - Onchocerciasis
Phase 3Active not recruitingMedicines Development for Global Health3232021-05-032025-12-23
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Moxidectin, Ivermectin, Albendazole - Onchocerciasis
Phase 3CompletedMedicines Development for Global Health129792021-05-032026-03-03
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
Ivermectin, Placebo, Dihydroartemisinin-piperaquine - Malaria,Falciparum, Neglected Tropical Diseases
Phase 3UnknownLondon School of Hygiene and Tropical Medicine240002021-05-032022-02-24
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL] - Trichuriasis, Ascariasis
Phase 2 / Phase 3CompletedJennifer Keiser5362021-03-012024-12-05
Moxidectin for LF, Cote d'Ivoire (DOLF)
Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis
Phase 3CompletedWashington University School of Medicine1642020-08-202026-01-29
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis
Phase 3CompletedThe Task Force for Global Health2352019-01-152021-06-24
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws
Phase 3CompletedLihir Medical Centre200002018-10-012019-02-28
Efficacy and Safety of IVM/ALB Co-administration
Albendazole, Albendazole and Ivermectin - Trichuriasis
Phase 2 / Phase 3CompletedJennifer Keiser16732018-09-092024-03-20
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
Doxycycline, Placebo - Lymphedema, Lymphatic Filariasis
Phase 3CompletedThe Task Force for Global Health2202018-06-192021-06-24

Showing 20 of 31. Sign in to see all of them.

Narrower conditions

Elephantiasis, Filarial (8)  ·  Trichuriasis (8)  ·  Ancylostomiasis (7)  ·  Hookworm Infections (7)  ·  Onchocerciasis (7)  ·  Strongyloidiasis (7)  ·  Filariasis (6)  ·  Ascariasis (5)  ·  Lymphedema (3)  ·  Scabies (3)  ·  Enterobiasis (2)  ·  Helminthiasis (2)  ·  Loiasis (2)  ·  Malaria (2)  ·  Neglected Diseases (2)

Broader conditions

Infections (31)  ·  Parasitic Diseases (31)  ·  Helminthiasis (29)  ·  Secernentea Infections (29)  ·  Spirurida Infections (16)  ·  Filariasis (10)  ·  Skin Diseases (10)  ·  Skin Diseases, Infectious (10)  ·  Skin Diseases, Parasitic (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Hemic and Lymphatic Diseases (9)  ·  Strongylida Infections (9)  ·  Vector Borne Diseases (9)  ·  Adenophorea Infections (8)

Interventions

Albendazole (17)  ·  Ivermectin (17)  ·  moxidectin (7)  ·  Doxycycline (3)  ·  Tablets (3)  ·  Albumins (2)  ·  Bay 44-4400 (2)  ·  Diethylcarbamazine (2)  ·  Intravital Microscopy (2)  ·  Mebendazole (2)  ·  emodepside (2)  ·  Azithromycin (1)  ·  Levamisole (1)  ·  Mass Drug Administration (1)  ·  Random Allocation (1)

Sponsors

Jennifer Keiser (6)  ·  Medicines Development for Global Health (4)  ·  The Task Force for Global Health (3)  ·  Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2)  ·  Swiss Tropical & Public Health Institute (2)  ·  University Hospitals Cleveland Medical Center (2)  ·  Albert Einstein College of Medicine (1)  ·  Centro per le Malattie Tropicali (1)  ·  Colorado State University (1)  ·  Hospital de Niños R. Gutierrez de Buenos Aires (1)  ·  Insud Pharma (1)  ·  Lihir Medical Centre (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  Mahidol University (1)  ·  Mundo Sano Foundation (1)

Countries

Côte d’Ivoire (4)  ·  Ghana (4)  ·  Tanzania (4)  ·  Democratic Republic of the Congo (3)  ·  India (2)  ·  Sri Lanka (2)  ·  Uganda (2)  ·  United States (2)  ·  Argentina (1)  ·  Benin (1)  ·  Burkina Faso (1)  ·  Fiji (1)  ·  Guinea-Bissau (1)  ·  Honduras (1)  ·  Italy (1)

Top investigators

Eric Ottesen, MD (3)  ·  Benjamin Koudou, PhD (2)  ·  Jennifer Keiser, Professor (2)  ·  Tony Ukety, MD, DO, MPH (2)  ·  Alejandro Javier Krolewiecki, PhD, MD (1)  ·  Alejandro Krolewiecki, MD (1)  ·  Anna R Last, MBChB PhD (1)  ·  Brian D. Foy, PhD (1)  ·  Catherine Bjerum, MD, MPH (1)  ·  Christina M Coyle, MD (1)  ·  Christopher L King, MD, PhD (1)  ·  Gabriela Matamoros, PhD, MSc, BSc (1)  ·  Hector Freilij, MD (1)

Results publications

PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 21572981, PMID 29346377, PMID 29361335, PMID 30878222, PMID 30885157, PMID 31558376, PMID 33137100, PMID 33930024, PMID 33979325, PMID 34191812, PMID 34226233, PMID 34281614, PMID 34403424, PMID 34632308, PMID 34856181, PMID 35217670, PMID 35476631, PMID 35701056, PMID 35803632, PMID 36354034, PMID 36461087, PMID 36897877, PMID 36917597, PMID 37036890, PMID 37357904, PMID 37419638, PMID 37616301, PMID 37721964, PMID 37899143, PMID 38175837, PMID 38319937, PMID 38517907, PMID 39242171, PMID 39380086, PMID 39551062, PMID 39591454, PMID 40345209, PMID 40615414, PMID 40675166, PMID 40752908, PMID 42264499, PMID 42684913, PMID 42848323

NIH funding

R01AI155739 (1)